Clinical trials: Locally Advanced Head and Neck Carcinoma
Head and Neck Neoplasms
Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer
To evaluate the efficacy of the concomitant combination of radiotherapy and docetaxel with or without cisplatin in terms of objective response rates (WHO criteria).
- Trial name
- TAX200006 (NCT00521521)
- Testing
- docetaxel and cisplatin, docetaxel
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Sanofi
Esophageal Cancer
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy.
- Trial name
- SORT (NCT07162506)
- Testing
- Surgery, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hypopharyngeal Carcinoma, Immunotherapy
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
This is a single-center, multidisciplinary, open-label, single-arm prospective clinical study.
- Conditions
- Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy
- Trial name
- NCT04156698
- Testing
- Docetaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Head and Neck Cancer
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
This is a non-randomized phase II study of targeted radiotherapy (RT) administered concurrently with panitumumab in patients with locally advanced squamous carcinoma of the head and neck.
- Trial name
- NCT01312493
- Testing
- Panitumumab, Intensity Modulated Radiation Therapy
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Cancer, Gastric Cancer
Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003055
- Testing
- cisplatin, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
HNSCC
The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma
For patients with locally advanced head and neck tumors who are over 70 years old, have PS>2, have hearing impairment, renal dysfunction, or have neuropathy greater than grade 1 that is intolerant to cisplatin, radiotherapy alone…
- Trial name
- NCT05831930
- Testing
- Nituozumab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
This phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with anaplastic thyroid cancer that is stage IVB and has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8
- Trial name
- NCT04171622
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
This is a Phase II treatment, randomized 3:1 ratio, open label clinical trial to study the effect of short duration administration of N-acetyl cysteine on oral microbiome and on mucositis caused by concurrent chemotherapy and…
- Trial name
- NCT03982537
- Testing
- N-Acetyl-L-Cysteine dietary supplement, Chemotherapy and Radiation
- Sponsor
- Wake Forest University Health Sciences
Esophageal Cancer
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous…
- Trial name
- BLESS (NCT06385730)
- Testing
- neoadjuvant anti-PD-1, neoadjuvant anti-PD-1 with LDRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Chest Hospital
Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
This was a phase II clinical study. Patients with histologically confirmed, resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) without distant metastasis were enrolled.
- Trial name
- NCT07780877
- Testing
- Standard adjuvant radiotherapy based on pathologic findings, De-escalated radiotherapy with a reduced dose, De-escalated radiotherapy with omission of ENI
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Fudan University
Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby…
- Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma
- Trial name
- NCT06959641
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jochen Lorch
Squamous Cell Carcinoma of Head and Neck
Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
Primary Objective: To evaluate the overall response rate (including complete response and partial response) of subjects treated with combination therapy docetaxel and cisplatin followed by the chemoradiotherapy in patients with…
- Trial name
- DECIDE (NCT02061631)
- Testing
- Cisplatin, DOCETAXEL XRP6976, Dexamethasone
- Where
- Pakistan
- Volunteers
- 35 people
- Sponsor
- Sanofi
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma…
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
- Trial name
- NCT05125055
- Testing
- Toripalimab (anti-programmed death-1 inhibitor), Albumin paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Squamous Cell Carcinoma
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Based on our previous single-arm Phase Ib study (CRIS trial, NCT06303583), we observed that neoadjuvant chemoradiotherapy followed by immunotherapy (nCRIT) significantly increased the pathological complete response (pCR) rate…
- Trial name
- NCT06509568
- Testing
- Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zhejiang Cancer Hospital
Squamous Cell Carcinoma of the Head and Neck
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
This is a phase 1 study of the drug dacomitinib with radiotherapy, with or without chemotherapy, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT01737008
- Testing
- dacomitinib, Radiotherapy, Cisplatin
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Locally Advanced Head and Neck Squamous Cell Carcinoma
Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
This clinical trial examines a group-mediated cognitive behavioral resistance exercise intervention in head and neck cancer patients who are undergoing chemoradiation treatment.
- Trial name
- NCT04733495
- Testing
- Counseling, Dietary Counseling and Surveillance, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Solid Tumors Cancer
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and…
- Trial name
- NCT04196283
- Testing
- ABBV-368, Tilsotolimod, Nab-paclitaxel
- Where
- 26 sites in United States, France and 4 more
- Volunteers
- 30 people
- Sponsor
- AbbVie
Head and Neck Cancer
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2.
- Trial name
- Dasatinib (NCT00882583)
- Testing
- Cetuximab, Dasatinib, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard treatment with chemotherapy and radiation.
- Trial name
- NCT00226239
- Testing
- Docetaxel, Cisplatin, Cetuximab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Esophageal Cancer, ESCC
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
This study will evaluate whether two positron emission tomography/computed tomography (PET/CT) scans performed before treatment-68Ga-FAPI and 18F-FDG-can help predict how well patients with resectable, locally advanced thoracic…
- Trial name
- NCT07770672
- Testing
- Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus Chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tan Lijie